ARGNF News and Press, Argen X NV From 04/17/23

Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

2023-03-31 07:58:34 ET Summary argenx is a clinical-stage biotech company focused on developing antibody-based therapies for severe autoimmune diseases using its SIMPLE Antibody platform. Efgartigimod, argenx's lead product candidate, is a novel FcRn antagonist approved for the tr...

March 17 , 20 2 3 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeting of shareho...

2023-03-16 14:15:32 ET Big pharma held steady on Thursday after the Centers for Medicare & Medicaid Services (CMS) issued initial guidance on the Medicare drug price negotiation program, which will go into effect in 2026. The program comes under President Biden's Inflation Reduc...

VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis ( gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti- AChR antibody positive gMG patient...

2023-03-06 17:07:59 ET Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the treatment of autoimmune diseases, including myasthenia gravis (MG). In batoclimab clinical trials by Immunovant, safety concerns emerged w...

argenx SE (ARGX) Q4 2022 Earnings Conference Call March 2, 2023 08:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Tazeen Ahmad...

The following slide deck was published by argenx SE in conjunction with their 2022 Q4 earnings call. For further details see: argenx SE 2022 Q4 - Results - Earnings Call Presentation

$ 1 7 3 million in fourth quarter and $ 401 million in full year 2022 VYVGART® (efgartigimod alfa- fcab ) global net product sales FDA review ongoing for SC efgartigimod BLA with PDUFA target action date of June 20, 2023...